Yarrow Bioscience Initiates Phase 2a/2b Trial for YB-101, Reports Cash Runway into 2028
YARW has more than doubled off its 52-week low of $14.025.
Summary
Yarrow Bioscience reported Q2 2026 results and a business update. The company initiated a Phase 2a/2b trial of YB-101, a potential first-in-class anti-TSHR antibody for Graves' disease and thyroid eye disease, with Phase 2a data expected in H2 2027. FDA granted Fast Track Designation for YB-101 in GD. Cash position of $18.7M as of June 30, 2026, plus $100M received in July from the second half of pre-merger financings, is expected to fund operations into 2028. Net loss was $6.5M for the quarter. The merger with VYNE Therapeutics is complete, and the company trades as YARW with approximately 28.6 million shares outstanding. This follows the recent 13D filing showing OrbiMed's 9.97% stake acquired through the merger. The trial initiation and extended cash runway are material positive developments for a clinical-stage biotech.
At the time of this announcement, YARW was trading at $42.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $114.2M. The 52-week trading range was $14.03 to $46.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.